NEWARK, Calif., July 21 /PRNewswire/ -- Novasys Medical, Inc., developer of the Renessa(R) treatment for female stress urinary incontinence, announced today that it has received $18.95 million in the second tranche of its previously announced Series D preferred stock financing. The Company received the first tranche of the Series D round in May 2008, with lead investor Versant Ventures and new investors ThreeArch Partners and Skyline Ventures. All three participated in the second tranche, with existing investors Alloy Ventures, Delphi Ventures, GBS Venture Partners and Hercules Technology Growth Capital.
"In this challenging financing environment, we greatly value the continued support of our investors. They understand the tremendous opportunity the non-surgical Renessa treatment offers women," said Debra Reisenthel, President and CEO of Novasys Medical. "This financing will speed the process of securing reimbursement for the Renessa treatment. Since the first tranche of the Series D financing closed last May, we've enjoyed major progress with several key payers agreeing to cover the procedure. These payers include Aetna, plus regional Medicare carriers Noridian , First Coast and TrailBlazers, who cover 27 million lives. Additional payers are expected to join them in covering Renessa soon."
Beckie Robertson, Managing Director with Versant Ventures, said, "We're really pleased with the reimbursement progress Novasys has made with payers in the past year. We're confident this is a huge opportunity in an underserved market."
Female Stress Urinary Incontinence (SUI)
SUI is the involuntary leakage of urine associated with coughing, sneezing, laughing and recreational activities. It is caused by a variety of factors---most commonly childbirth---and often restricts the social, professional, and personal lives of an estimated 15 million women in th
|SOURCE Novasys Medical, Inc.|
Copyright©2009 PR Newswire.
All rights reserved